AU2003207973A1 - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases - Google Patents
Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseasesInfo
- Publication number
- AU2003207973A1 AU2003207973A1 AU2003207973A AU2003207973A AU2003207973A1 AU 2003207973 A1 AU2003207973 A1 AU 2003207973A1 AU 2003207973 A AU2003207973 A AU 2003207973A AU 2003207973 A AU2003207973 A AU 2003207973A AU 2003207973 A1 AU2003207973 A1 AU 2003207973A1
- Authority
- AU
- Australia
- Prior art keywords
- diagnosing
- methods
- same
- antibodies directed
- associated diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004203461A AU2004203461B2 (en) | 2002-01-31 | 2004-07-29 | Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35257802P | 2002-01-31 | 2002-01-31 | |
| US60/352,578 | 2002-01-31 | ||
| US39226602P | 2002-07-01 | 2002-07-01 | |
| US60/392,266 | 2002-07-01 | ||
| US10/235,852 | 2002-09-06 | ||
| US10/235,852 US20040052928A1 (en) | 2002-09-06 | 2002-09-06 | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
| US43645302P | 2002-12-27 | 2002-12-27 | |
| US60/436,453 | 2002-12-27 | ||
| PCT/IL2003/000079 WO2003063760A2 (en) | 2002-01-31 | 2003-01-30 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004203461A Division AU2004203461B2 (en) | 2002-01-31 | 2004-07-29 | Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003207973A1 true AU2003207973A1 (en) | 2003-09-02 |
Family
ID=27671045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003207973A Abandoned AU2003207973A1 (en) | 2002-01-31 | 2003-01-30 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1534310A4 (en) |
| JP (1) | JP2006506942A (en) |
| KR (1) | KR20040081165A (en) |
| AU (1) | AU2003207973A1 (en) |
| CA (1) | CA2473987C (en) |
| WO (1) | WO2003063760A2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8012929B2 (en) | 2002-01-31 | 2011-09-06 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated diseases |
| US8563273B2 (en) | 2002-09-06 | 2013-10-22 | Tel Aviv University Future Technology Development L.P. | Method of screening for compounds that disaggregate amyloid aggregates |
| US8697634B2 (en) | 2002-01-31 | 2014-04-15 | Tel Aviv University Future Technology Development L.P. | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease |
| US9096645B2 (en) | 2010-11-15 | 2015-08-04 | Ramot At Tel-Aviv University Ltd. | Dipeptide analogs for treating conditions associated with amyloid fibril formation |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| EP2058275A1 (en) | 2003-01-07 | 2009-05-13 | Ramot at Tel-Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| WO2005031362A2 (en) | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| EP1973928A2 (en) | 2005-10-11 | 2008-10-01 | Ramot at Tel-Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
| US8101578B2 (en) | 2006-04-28 | 2012-01-24 | Kagoshima University | Amyloid [β] Beta fibrillogenesis-inhibiting peptide |
| CN101668525A (en) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ES2548913T3 (en) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Heterocyclic derivatives such as glutaminyl cyclase inhibitors |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| CA2789440C (en) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| JP5945532B2 (en) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| CN103282349A (en) * | 2010-10-29 | 2013-09-04 | 德国麦氏大药厂 | Indole derivatives and process for their preparation |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| KR102117969B1 (en) * | 2012-09-12 | 2020-06-04 | 뉴리뮨 홀딩 아게 | Human islet amyloid polypeptide(hiapp) specific antibodies and uses thereof |
| KR101956302B1 (en) * | 2016-11-30 | 2019-03-11 | 연세대학교 산학협력단 | intracellular pH-responsive fusion peptide, phamaceutical composition for treatment of protein aggregation and misfolding related diseases |
| AU2018314269B2 (en) * | 2017-08-11 | 2022-12-08 | University Of Kentucky Research Foundation | Anti-neurodegenerative therapeutic, method of manufacture, and use |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| TW202144387A (en) * | 2020-02-11 | 2021-12-01 | 美商聯合生物醫學公司 | Peptide immunogens targeting islet amyloid polypeptide (iapp) and formulations thereof for prevention and treatment of disorders related to aggregated iapp |
| EP4630812A1 (en) * | 2022-12-05 | 2025-10-15 | Neurimmune AG | Cyclic compounds and their use in assays for detecting antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6344895A (en) * | 1986-08-13 | 1988-02-25 | Kyowa Hakko Kogyo Co Ltd | Anti-amyloid A protein monoclonal antibody |
| AU7261994A (en) * | 1993-07-19 | 1995-02-20 | Resolution Pharmaceuticals Inc. | Hydrazino-type radionuclide chelators having an n3s configuration |
| US6303567B1 (en) * | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| AU716564B2 (en) * | 1996-11-06 | 2000-03-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Protease-activatable pseudomonas exotoxin A-like proproteins |
| JP2000193661A (en) * | 1998-12-25 | 2000-07-14 | Tokyo Rika Kikai Kk | Inspecting method for dementia |
-
2003
- 2003-01-30 AU AU2003207973A patent/AU2003207973A1/en not_active Abandoned
- 2003-01-30 JP JP2003563456A patent/JP2006506942A/en active Pending
- 2003-01-30 WO PCT/IL2003/000079 patent/WO2003063760A2/en not_active Ceased
- 2003-01-30 CA CA2473987A patent/CA2473987C/en not_active Expired - Fee Related
- 2003-01-30 KR KR10-2004-7011868A patent/KR20040081165A/en not_active Ceased
- 2003-01-30 EP EP03704977A patent/EP1534310A4/en not_active Withdrawn
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8012929B2 (en) | 2002-01-31 | 2011-09-06 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated diseases |
| US8697634B2 (en) | 2002-01-31 | 2014-04-15 | Tel Aviv University Future Technology Development L.P. | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease |
| US8993510B2 (en) | 2002-01-31 | 2015-03-31 | Tel Aviv University Future Technology Development L.P. | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease |
| US8563273B2 (en) | 2002-09-06 | 2013-10-22 | Tel Aviv University Future Technology Development L.P. | Method of screening for compounds that disaggregate amyloid aggregates |
| US9096645B2 (en) | 2010-11-15 | 2015-08-04 | Ramot At Tel-Aviv University Ltd. | Dipeptide analogs for treating conditions associated with amyloid fibril formation |
| US9630989B2 (en) | 2010-11-15 | 2017-04-25 | Ramot At Tel-Aviv University Ltd. | Dipeptide analogs for treating conditions associated with amyloid fibril formation |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1534310A4 (en) | 2006-05-31 |
| WO2003063760A2 (en) | 2003-08-07 |
| CA2473987A1 (en) | 2003-08-07 |
| EP1534310A2 (en) | 2005-06-01 |
| CA2473987C (en) | 2013-11-19 |
| JP2006506942A (en) | 2006-03-02 |
| WO2003063760A3 (en) | 2005-02-10 |
| KR20040081165A (en) | 2004-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1638517A4 (en) | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | |
| AU2003207973A1 (en) | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | |
| AU2003217608A1 (en) | Method and apparatus for body sound analysis | |
| AU2003287642A1 (en) | Process for solubilizing protein | |
| AU2003294601A1 (en) | Method and system for parts analysis | |
| AU2003245689A1 (en) | Method for testing the integrity of dpf's | |
| AU2003282642A1 (en) | Blood testing apparatus | |
| AU2002952747A0 (en) | Method for analysing peptides | |
| AU2002317105A1 (en) | Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors | |
| AU2003258250A1 (en) | Apparatus for multifocal deposition and analysis and methods for its use | |
| AU2002364749A1 (en) | Method for protein expression analysis | |
| AU2003273841A1 (en) | Method for identifying bhs-specific proteins and fragments thereof | |
| AU2003264657A1 (en) | Method for designing peptides | |
| AU2003292231A1 (en) | Methods for diagnosing and treating schizophrenia | |
| EP1532173A4 (en) | Protein analysis | |
| AU2002367604A1 (en) | Apparatus and method for designing proteins and protein libraries | |
| AU2003271261A1 (en) | Method and device for diagnosing oncological diseases | |
| AU2003240558A1 (en) | Biological results evaluation method | |
| AU2003252383A1 (en) | Test piece for protein assay and process for producing the same | |
| AU2003288929A1 (en) | Methods and kits for detecting proteins | |
| AU2003252075A1 (en) | Human immunosuppressive protein | |
| AU2003294206A1 (en) | Methods for diagnosing htlv-i-mediated diseases | |
| IL163285A (en) | Peptides, antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | |
| IL172788A0 (en) | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | |
| AU2003236374A1 (en) | Atopic dermatitis-inducing proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |